title: The Five-Times-Sit-to-Stand test, a marker of global cognitive functioning among community-dwelling older women.
abstract: OBJECTIVE
  To determine whether there was an association between the Five-Times-Sit-to-Stand test (FTSS) and the global cognitive function assessed with Short-Portable-Mental-State-Questionnaire (SPMSQ) among the EPIDOS cohort.
  
  
  METHODS
  Cross-sectional study corresponding to the baseline assessment of the EPIDOS study.
  
  
  METHODS
  Five French cities including Amiens, Lyon, Montpellier, Paris and Toulouse.
  
  
  METHODS
  7421 community-dwelling older women (mean age 80.41 ± 0.04 years).
  
  
  METHODS
  Time to achieve FTSS, and SPMSQ score. Age, body mass index, high number of comorbidities, cardiovascular risk factors, depression, regular physical activity, joint pain, quadriceps strength, visual acuity, use of psychoactive drugs, serum albumin, vitamin D deficiency (i.e., serum concentration < 10 ng/mL), and the influence of seasons and study centers were used as covariables. Subjects were divided into 2 groups according to SPMSQ score (either impaired < 8/10 or normal ≥ 8/10).
  
  
  RESULTS
  Compared to their counterparts, the women with cognitive impairment (n=1190, mean 81.51 ± 0.45 years) took more time in performing FTSS (17.8± 0.9 seconds versus 16.1 ± 0.3 seconds, P < 0.001). There was a significant negative association of SPMSQ score with FTSS (Unadjusted β=-0.02(95%CI -0.03;-0.01), P< 0.001; Fully Adjusted β=-0.03(95%CI -0.05;-0.01), P=0.003; Stepwise Backward Adjusted β=-0.02(95%CI -0.04;-0.01), P=0.005), as well as with advance in age (β=-0.04, P=0.006) and vitamin D deficiency (β=-0.34, P=0.011). The FTSS limit value in predicting moderate cognitive impairment was set at 15 seconds by a sensitivity analysis (negative predictive value=86%).
  
  
  CONCLUSIONS
  We found a negative association of FTSS with global cognitive performance. Achieving FTSS in less than 15 seconds made unlikely the existence of a moderate cognitive impairment. FTSS could be used as a tool in primary care medicine to exclude moderate cognitive decline.
authors: Department of Internal Medicine and Geriatrics, Angers University Hospital, Angers, France. CeAnnweiler@chu-angers.fr
authors: C
authors: C
authors: Annweiler
authors: A-M
authors: AM
authors: Schott
authors: G
authors: G
authors: Abellan van Kan
authors: Y
authors: Y
authors: Rolland
authors: H
authors: H
authors: Blain
authors: B
authors: B
authors: Fantino
authors: F R
authors: FR
authors: Herrmann
authors: O
authors: O
authors: Beauchet
mesh_terms: D000369:Aged, 80 and over; D000375:Aging / Q000502:physiology / Q000523:psychology; D003072:Cognition Disorders / Q000175:diagnosis*; D015331:Cohort Studies; D003430:Cross-Sectional Studies; D005260:Female; D015577:Geriatric Assessment; D006304:Health Status; D006801:Humans; D008297:Male; D018482:Muscle, Skeletal / Q000502:physiology*; D010809:Physical Fitness; D011187:Posture / Q000502:physiology*; D011930:Reaction Time; D013647:Task Performance and Analysis; D014808:Vitamin D Deficiency / Q000150:complications